BioSpace News Archive

Advicenne (Paris:ADVIC) (Euronext: ADVIC), specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces today that it has received authorization from the Belgian health authority (FAMHP) to begin a pivotal Phase II/III CORAL clinical trial in cystinuria with its flagship drug candidate, ADV7103. The French pharmaceutical company also assesses its financial visibility at the close of 2018.

VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its participation in the prestigious J.P. Morgan Healthcare annual conference for the second year running, which will take place from 7 to 10 January 2019 at the Westin St. Francis Hotel in San Francisco in California.

Meditation Studio, a 5-star rated meditation app that makes meditation simple and accessible, with more than 500 guided meditations and 6 courses, announces two new sleep collections - Goodnight Kiddo and Deep Sleep - along with a new Night Mode feature to help both kids and grown-ups fall asleep.

PolarityTE, Inc. announced the appointment of Jon Burrows, PhD as President of Contract Services and Senior Vice President of Corporate Development.

First Human dMAb Study Will Target Zika Infection

Diplomat Pharmacy, Inc. (NYSE: DPLO), is updating its 2018 financial guidance and providing a preliminary 2019 outlook in connection with its presentation today at the JP Morgan Healthcare Conference in San Francisco.

With rising drug prices and low patient response rates, Scipher Medicine is bringing precision medicine to autoimmune diseases by ensuring patients are prescribed optimal treatment from day one while avoiding side effects and the billions of dollars that payers and patients waste each year on ineffective treatments.

IQVIA™ (NYSE:IQV) today announced that more than 30 life sciences companies have selected Orchestrated Customer Engagement (OCE) as their commercial solution in the 12 months since the groundbreaking technology first launched

The small size of sdAbs may enable the generation of more complex CAR T cell products such as those designed to combine additional functions into a single CAR molecule or recognize multiple tumor antigens simultaneously.

Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration.